↓ Skip to main content

Pharmaceutical production of anti-tumor and immune-potentiating Enterococcus faecalis-2001 β-glucans: enhanced activity of macrophage and lymphocytes in tumor-implanted mice.

Overview of attention for article published in Current Pharmaceutical Biotechnology, October 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#6 of 573)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
4 news outlets
twitter
2 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pharmaceutical production of anti-tumor and immune-potentiating Enterococcus faecalis-2001 β-glucans: enhanced activity of macrophage and lymphocytes in tumor-implanted mice.
Published in
Current Pharmaceutical Biotechnology, October 2017
DOI 10.2174/1389201018666171002130428
Pubmed ID
Authors

Gu, Yeun-Hwa, Choi, Hyunju, Yamashita, Takenori, Kang, Ki-Mun, Iwasa, Masahiro, Lee, Moon-Jo, Lee, Kyoung Hae, Kim, Cheorl-Ho, Yeun-Hwa Gu, Hyunju Choi, Takenori Yamashita, Ki-Mun Kang, Masahiro Iwasa, Moon-Jo Lee, Kyoung Hae Lee, Cheorl-Ho Kim

Abstract

Enterococcus faecalis 2001 is a probiotic lactic acid bacterium and has been used as a biological response modifier (BRM). From physiological limitation of bacterial preservation in storage and safety, the live E. faecalis 2001 has been heat-treated and the BRM components containing high level of β-glucan, named EF-2001, has been prepared. The heat-treated EF-2001 has been examined for the antioxidative potential for radical scavenging and anti-tumor activities as well as immune-enhancing response in mice. The lymphocyte versus polymorphonuclear leukocyte ratios was increased in mice upon treatment with EF-2001. The number of lymphocytes was increased in the EF-2001-treated group. In the mice bearing two different Ehrlich solid and Sarcoma-180 carcinomas, the treatment with EF-2001 resulted in anti-tumor action. Tumor-suppressive capacity upon treatment with EF-2001 was significantly increased compared to normal controls. During the time interval administration of 5 weeks between priming and secondary administration of EF-2001, the expression and production levels of TNF- were also observed in the EF-2001-administered mice. Additionally, anti-tumor activity examined with the intravenous administration of EF 2001 with a 34 time intervals was also observed, as the growth of Sarcoma180 cells was clearly inhibited by the EF-2001. From the results, it was suggested that the immune response is enhanced from the anti-oxidative provoked by the EF-2001 and anti-tumor activity is provoked through NK cells and TNF -.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 67%
Other 1 33%
Student > Doctoral Student 1 33%
Student > Master 1 33%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 67%
Pharmacology, Toxicology and Pharmaceutical Science 1 33%
Agricultural and Biological Sciences 1 33%
Medicine and Dentistry 1 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2017.
All research outputs
#402,896
of 12,167,359 outputs
Outputs from Current Pharmaceutical Biotechnology
#6
of 573 outputs
Outputs of similar age
#18,544
of 271,870 outputs
Outputs of similar age from Current Pharmaceutical Biotechnology
#1
of 6 outputs
Altmetric has tracked 12,167,359 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 573 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,870 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them